B
BOSTON SCIENTIFIC CORP
NYSE: BSX (Boston Scientific Corporation)
Last update: yesterday, 6:58AM76.85
1.10 (1.45%)
| Previous Close | 75.75 |
| Open | 75.27 |
| Volume | 21,466,610 |
| Avg. Volume (3M) | 13,973,219 |
| Market Cap | 114,036,596,736 |
| Price / Earnings (TTM) | 39.61 |
| Price / Earnings (Forward) | 22.03 |
| Price / Sales | 5.64 |
| Price / Book | 4.64 |
| 52 Weeks Range | |
| Earnings Date | 22 Apr 2026 |
| Profit Margin | 11.58% |
| Operating Margin (TTM) | 20.09% |
| Diluted EPS (TTM) | 1.37 |
| Quarterly Revenue Growth (YOY) | 20.90% |
| Quarterly Earnings Growth (YOY) | 36.20% |
| Total Debt/Equity (MRQ) | 52.16% |
| Current Ratio (MRQ) | 1.45 |
| Operating Cash Flow (TTM) | 3.81 B |
| Levered Free Cash Flow (TTM) | 2.32 B |
| Return on Assets (TTM) | 5.28% |
| Return on Equity (TTM) | 9.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Boston Scientific Corporation | Bearish | Bearish |
AIStockmoo Score
0.5
| Analyst Consensus | 4.0 |
| Insider Activity | -4.0 |
| Price Volatility | 5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 0.50 |
|
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Large Core |
| % Held by Insiders | 0.18% |
| % Held by Institutions | 93.22% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bollard Group Llc | 31 Dec 2025 | 19,000,469 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 124.00 (Barclays, 61.35%) | Buy |
| Median | 102.00 (32.73%) | |
| Low | 94.00 (Wells Fargo, 22.32%) | Buy |
| Average | 106.24 (38.24%) | |
| Total | 17 Buy | |
| Avg. Price @ Call | 78.79 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 17 Feb 2026 | 109.00 (41.83%) | Buy | 76.29 |
| 05 Feb 2026 | 112.00 (45.74%) | Buy | 77.64 | |
| BTIG | 09 Feb 2026 | 110.00 (43.14%) | Buy | 74.12 |
| 04 Feb 2026 | 110.00 (43.14%) | Buy | 75.50 | |
| Baird | 05 Feb 2026 | 101.00 (31.42%) | Buy | 77.64 |
| Citigroup | 05 Feb 2026 | 102.00 (32.73%) | Buy | 77.64 |
| Evercore ISI Group | 05 Feb 2026 | 96.00 (24.92%) | Buy | 77.64 |
| JP Morgan | 05 Feb 2026 | 100.00 (30.12%) | Buy | 77.64 |
| Mizuho | 05 Feb 2026 | 115.00 (49.64%) | Buy | 77.64 |
| Morgan Stanley | 05 Feb 2026 | 118.00 (53.55%) | Buy | 77.64 |
| Needham | 05 Feb 2026 | 97.00 (26.22%) | Buy | 77.64 |
| RBC Capital | 05 Feb 2026 | 115.00 (49.64%) | Buy | 77.64 |
| 17 Dec 2025 | 130.00 (69.16%) | Buy | 94.48 | |
| Stifel | 05 Feb 2026 | 110.00 (43.14%) | Buy | 77.64 |
| TD Cowen | 05 Feb 2026 | 100.00 (30.12%) | Buy | 77.64 |
| Truist Securities | 05 Feb 2026 | 95.00 (23.62%) | Buy | 77.64 |
| 18 Dec 2025 | 120.00 (56.15%) | Buy | 96.11 | |
| UBS | 05 Feb 2026 | 120.00 (56.15%) | Buy | 77.64 |
| Wells Fargo | 05 Feb 2026 | 94.00 (22.32%) | Buy | 77.64 |
| Barclays | 03 Feb 2026 | 124.00 (61.35%) | Buy | 91.62 |
| Oppenheimer | 16 Jan 2026 | 100.00 (30.12%) | Buy | 88.07 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BROWN VANCE R | - | 74.73 | -890 | -66,510 |
| BUTCHER ARTHUR C | - | 74.73 | -1,229 | -91,843 |
| FITZGERALD JOSEPH MICHAEL | - | 74.73 | -1,806 | -134,962 |
| MAHONEY MICHAEL F | - | 74.73 | -7,865 | -587,751 |
| MONSON JONATHAN | - | 74.73 | -440 | -32,881 |
| O'CONNOR PADRAIG ANDREW | - | 74.73 | -339 | -25,333 |
| O'SULLIVAN MIRIAM | - | 74.73 | -291 | -21,746 |
| WOODWORTH EMILY | - | 74.73 | -283 | -21,149 |
| Aggregate Net Quantity | -13,143 | |||
| Aggregate Net Value ($) | -982,176 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 74.73 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BROWN VANCE R | Officer | 16 Feb 2026 | Disposed (-) | 890 | 74.73 | 66,510 |
| BROWN VANCE R | Officer | 16 Feb 2026 | Option execute | 1,839 | - | - |
| BUTCHER ARTHUR C | Officer | 16 Feb 2026 | Disposed (-) | 1,229 | 74.73 | 91,843 |
| BUTCHER ARTHUR C | Officer | 16 Feb 2026 | Option execute | 2,546 | - | - |
| WOODWORTH EMILY | Officer | 16 Feb 2026 | Disposed (-) | 283 | 74.73 | 21,149 |
| WOODWORTH EMILY | Officer | 16 Feb 2026 | Option execute | 637 | - | - |
| MAHONEY MICHAEL F | Officer | 16 Feb 2026 | Disposed (-) | 7,865 | 74.73 | 587,751 |
| MAHONEY MICHAEL F | Officer | 16 Feb 2026 | Option execute | 16,265 | - | - |
| FITZGERALD JOSEPH MICHAEL | Officer | 16 Feb 2026 | Disposed (-) | 1,806 | 74.73 | 134,962 |
| FITZGERALD JOSEPH MICHAEL | Officer | 16 Feb 2026 | Option execute | 3,960 | - | - |
| O'CONNOR PADRAIG ANDREW | Officer | 16 Feb 2026 | Disposed (-) | 339 | 74.73 | 25,333 |
| O'CONNOR PADRAIG ANDREW | Officer | 16 Feb 2026 | Option execute | 905 | - | - |
| O'SULLIVAN MIRIAM | Officer | 16 Feb 2026 | Disposed (-) | 291 | 74.73 | 21,746 |
| O'SULLIVAN MIRIAM | Officer | 16 Feb 2026 | Option execute | 990 | - | - |
| MONSON JONATHAN | Officer | 16 Feb 2026 | Disposed (-) | 440 | 74.73 | 32,881 |
| MONSON JONATHAN | Officer | 16 Feb 2026 | Option execute | 990 | - | - |
| Show more | ||||||
| Date | Type | Details |
|---|---|---|
| 04 Feb 2026 | Announcement | Boston Scientific announces results for fourth quarter and full year 2025 |
| 15 Jan 2026 | Announcement | Boston Scientific announces agreement to acquire Penumbra, Inc. |
| 12 Jan 2026 | Announcement | Boston Scientific Announces Agreement to Acquire Valencia Technologies Corporation |
| 02 Jan 2026 | Announcement | Boston Scientific announces participation in the J.P. Morgan Healthcare Conference and conference call discussing fourth quarter and full year 2025 results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |